Aug 21 (Reuters) - ProMIS Neurosciences Inc PMN.TO :
* PROMIS NEUROSCIENCES OLIGOMER SELECTIVE ANTIBODY THERAPEUTIC FOR ALZHEIMER'S DISEASE, PMN310, SHOWS POTENTIAL FOR IMPROVED SAFETY PROFILE IN DIRECT COMPARISON TO OTHER AMYLOID BETA-DIRECTED ANTIBODIES IN CLINICAL DEVELOPMENT
* PROMIS NEUROSCIENCES-PMN310 SHOWED NO BINDING TO AMYLOID BETA PLAQUE IN AD BRAIN SAMPLES IN CONTRAST TO BAN2401 & ADUCANUMAB